Colinz Laboratories Ltd (531210)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Colinz Laboratories' revenue was ₹1.2 Cr (-21.0% year on year, -29.1% on the previous quarter), and net profit ₹2.4 Cr; the operating margin was 5.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1.2 | -21.0% | -29.1% |
| Operating profit | ₹0.1 | -51.8% | -30.4% |
| Net profit | ₹2.4 | — | — |
| EPS (₹) | 9.53 | — | — |
| Operating margin | 5.0% | — | — |
📢 Recent Corporate Announcements
Colinz Laboratories Limited submitted a compliance filing stating that disclosures under Regulation 23(9) regarding Related Party Transactions are not applicable to the company for the quarter ended September 30, 2026. The company claimed exemption under Regulation 15(2)(a) of SEBI (LODR) Regulations, 2015, which exempts entities below specified paid-up capital and net worth thresholds. Consequently, corporate governance provisions under Regulations 17 to 27 do not apply. This is an administrative compliance update with zero financial impact on the company.
- Declared non-applicability of Related Party Transaction disclosures under Regulation 23(9) of SEBI LODR for the quarter ended September 30, 2026
- Exemption claimed under Regulation 15(2)(a) of SEBI LODR Regulations, 2015
- Compliance provisions specified under Regulations 17 to 27 are declared non-applicable
- Filing dated October 1, 2026, submitted to BSE
Colinz Laboratories Limited submitted a compliance filing stating that disclosures under Regulation 23(9) regarding Related Party Transactions are not applicable to the company for the quarter ended September 30, 2026. The company claimed exemption under Regulation 15(2)(a) of SEBI (LODR) Regulations, 2015, which exempts entities below specified paid-up capital and net worth thresholds. Consequently, corporate governance provisions under Regulations 17 to 27 do not apply. This is an administrative compliance update with zero financial impact on the company.
- Declared non-applicability of Related Party Transaction disclosures under Regulation 23(9) of SEBI LODR for the quarter ended September 30, 2026
- Exemption claimed under Regulation 15(2)(a) of SEBI LODR Regulations, 2015
- Compliance provisions specified under Regulations 17 to 27 are declared non-applicable
- Filing dated October 1, 2026, submitted to BSE
Colinz Laboratories Limited has released its 40th Annual Report for FY 2025-26 and scheduled its Annual General Meeting (AGM) for September 22, 2026. Key agenda items include the adoption of FY26 annual accounts, the appointment of Mrs. Vijaya Mani as a Promoter Non-Executive Director, and the re-appointment of Mr. N. K. Menon as Whole-Time Director & CEO for one year through September 30, 2027. Financial statements confirm FY26 revenue from operations at Rs 6.53 Cr (up from Rs 6.14 Cr in FY25) and reflect an advance of Rs 1.06 Cr received towards the sale of factory premises.
- 40th AGM scheduled for September 22, 2026, via Video Conferencing / OAVM.
- Reported FY26 Revenue from Operations of Rs 652.77 Lacs compared to Rs 613.61 Lacs in FY25.
- Proposed reappointment of Mr. N. K. Menon as WTD & CEO for 1 year from October 1, 2026, to September 30, 2027.
- Balance sheet notes disclose an advance of Rs 105.84 Lacs received towards the sale of factory premises.
- Regularization of Mrs. Vijaya Mani as Non-Executive Promoter Director.
Colinz Laboratories Limited has scheduled its 40th Annual General Meeting (AGM) for September 22, 2026, to be held via Video Conferencing. The company announced a book closure period from September 15, 2026, to September 22, 2026 (both days inclusive) for AGM purposes. The cut-off date to determine shareholder eligibility for remote e-voting is September 15, 2026. Remote e-voting will run from September 19, 2026 (9:00 AM IST) to September 21, 2026 (5:00 PM IST).
- 40th AGM scheduled for September 22, 2026 at 2:30 PM IST via VC/OAVM
- Share transfer books and register of members closed from September 15, 2026 to September 22, 2026
- E-voting cut-off date fixed as September 15, 2026
- Remote e-voting window open from September 19, 2026 (9:00 AM IST) to September 21, 2026 (5:00 PM IST)
Colinz Laboratories Limited has issued the notice for its 40th Annual General Meeting scheduled for September 22, 2026, via video conferencing. Key agenda items include the adoption of FY26 audited financial statements and the regularisation of Mrs. Vijaya Mani as a Non-Executive Promoter Director. Additionally, the company seeks shareholder approval to re-appoint Mr. N. K. Menon as Whole-Time Director & CEO for a 1-year tenure from October 1, 2026, to September 30, 2027.
- 40th Annual General Meeting scheduled on Tuesday, 22nd September, 2026 at 2:30 PM IST via VC/OAVM
- Re-appointment of Mr. N. K. Menon as Whole-Time Director & CEO for 1 year (1st October 2026 to 30th September 2027)
- Appointment of Mrs. Vijaya Mani (DIN: 11363910) as Director (Promoter, Non-Executive)
- Speaker registration window open from 10th September 2026 (9:00 AM) to 12th September 2026 (5:00 PM)
The Dugar family (Acquirers) has issued a reminder advertisement for their open offer to acquire 6,54,966 shares, representing a 26% stake in Colinz Laboratories. The offer price is fixed at ₹54 per share, totaling ₹3.54 Cr, which is approximately 17.7% of the company's current market capitalization of ₹20 Cr. Notably, the offer price is at a significant discount of approximately 32% to the current market price of ₹79.7. This mandatory offer follows a shift in the promoter holding structure, which recently decreased from 66% to 50.6%.
- Open offer to acquire up to 6,54,966 fully paid-up equity shares, representing 26% of voting capital.
- Offer price set at ₹54 per share, a ~32% discount to the current market price of ₹79.7.
- Total offer consideration aggregates to ₹3,53,68,164 (₹3.54 Cr).
- Reminder advertisement published on August 12, 2026, in Financial Express, Jansatta, and Pratahkal.
- Acquirers include Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, with Padam Dugar as PAC.
Annjana Dugar, Likhitta Dugar, and Antariksh Dugar (the Acquirers) have announced an open offer to acquire up to 6,54,966 shares of Colinz Laboratories, representing 26% of the voting share capital. The offer price is set at ₹54 per share, which is a significant discount to the current market price of ₹81.7. The total offer size is valued at approximately ₹3.54 crore. This follows a recent decline in promoter holding from 66.0% in March 2026 to 50.6% in June 2026.
- Open offer to acquire 6,54,966 fully paid-up equity shares representing 26% of voting capital
- Offer price fixed at ₹54 per share, totaling an aggregate value of ₹3,53,68,164
- Acquirers include Annjana Dugar, Likhitta Dugar, and Antariksh Dugar with Padam Dugar as PAC
- Offer price represents a ~34% discount to the current market price of ₹81.7
- Public announcement published on August 06, 2026, in Financial Express and other newspapers
The Dugar family (Acquirers) has issued a formal Letter of Offer to acquire up to 6,54,966 shares, representing 26% of the voting capital of Colinz Laboratories. The offer price is set at ₹54 per share, which is a significant 32.5% discount to the current market price of ₹80. The total consideration for the offer amounts to ₹3.54 crore, representing approximately 17.7% of the company's current market capitalization of ₹20 crore. This follows a recent drop in promoter holding from 66.0% to 50.6% in the June 2026 quarter.
- Open offer to acquire 6,54,966 fully paid-up equity shares at ₹54 each
- Offer represents 26% of the total voting share capital of the company
- Total offer consideration aggregates to ₹3,53,68,164
- Offer price of ₹54 is at a 32.5% discount to the current market price of ₹80
- Promoter holding decreased from 66.0% in March 2026 to 50.6% in June 2026
Colinz Laboratories held a board meeting on July 30, 2026, to approve the un-audited financial results for the quarter ended June 30, 2026. The board confirmed the 40th Annual General Meeting (AGM) for September 22, 2026, and set the share transfer book closure from September 15 to September 22, 2026. Key leadership decisions include the re-appointment of Mr. N. K. Menon as CEO for a one-year term and the appointment of Mrs. Vijaya Mani as a Promoter Director. New internal and secretarial auditors were also appointed for the 2026-27 financial year.
- Re-appointment of Mr. N. K. Menon as Whole-time Director and CEO for a 1-year term effective October 1, 2026
- 40th Annual General Meeting (AGM) to be held on September 22, 2026, via video conferencing
- Book closure for the AGM set from September 15, 2026, to September 22, 2026
- Cut-off date for e-voting eligibility fixed as September 15, 2026
- Appointment of CA Ajay Ramsevak Sharma as Internal Auditor for FY 2026-27
Colinz Laboratories held its board meeting on July 30, 2026, approving the un-audited financial results for the quarter ended June 30, 2026. The board re-appointed Mr. N. K. Menon as Whole-time Director and CEO for a further one-year term effective October 1, 2026. Additionally, the company scheduled its 40th Annual General Meeting (AGM) for September 22, 2026, and appointed new internal and secretarial auditors for FY27. Mrs. Vijaya Mani was also appointed as a Promoter and Non-Executive Director.
- Approved un-audited financial results for the quarter ended June 30, 2026
- Re-appointed Mr. N. K. Menon as CEO for a 1-year term from October 1, 2026, to September 30, 2027
- Scheduled the 40th Annual General Meeting for September 22, 2026, via video conferencing
- Fixed September 15, 2026, as the cut-off date for determining shareholder eligibility for e-voting
- Appointed CA Ajay Ramsevak Sharma as Internal Auditor for the financial year 2026-27
Colinz Laboratories has scheduled a board meeting on July 30, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The board will also review the Director's Report and other statutory documents for the fiscal year ended March 31, 2026. Key administrative decisions, including fixing the Book Closure and Record Date for the upcoming Annual General Meeting (AGM), are on the agenda. Additionally, the company will recommend the appointment of internal and secretarial auditors for the 2026-27 financial year.
- Board meeting scheduled for July 30, 2026, at 3:30 p.m. at the Mumbai registered office
- Agenda includes approval of Un-Audited Financial Results for the quarter ended June 30, 2026
- Board to finalize the Director's Report and Corporate Governance Report for the year ended March 31, 2026
- Appointment of CA. Ajay Ramsevan Sharma as Internal Auditor for FY 2026-27 to be recommended
- Trading window closure, effective since June 30, 2026, will end 48 hours after the results are declared
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
